Table 1.

Schedule summary.

Visit	0	1	2	3	4	5	6	UV *
Week	−7	1	5	9	13	25	37	-
Visit Window	-	2	±7	±7	±7	±7	±7	-
Informed consent for the study	●
Demographic information	●
Participation in other clinical trials	●
Medical history	●
Confirmation of diagnosis of COVID-19 infection	●
Medication history	●
Vital signs	●	●	●	●	●	●	●	●
Electrocardiogram	●				●			●
Laboratory test	●				●			●
Blood collection for immune response and metabolite analysis	●				●	●	●	●
Pregnancy **	●
Evaluation of fatigue or brain fog	●
CIS	●		●	●	●	●	●	●
VAS (0–100) score for fatigue or brain fog	●		●	●	●	●	●	●
Inclusion/exclusion criteria	●
KM syndrome differentiation		●
Prescription of herbal medicine ***		●	○	○
Drug adherence			●	●	●			●
Check for combination therapy			●	●	●	●	●	●
ChFQ		●	●	●	●	●	●	●
EQ-5D-5L		●	●	●	●	●	●	●
PSQI-K		●	●	●	●	●	●	●
K-MoCA		●	●	●	●	●	●	●
CFQ		●					●	●
BDI		●	●	●	●	●	●	●
Digit span test in K-WAIS (DF, DB, and DF-DB)		●			●	●	●
K-BNT-15		●			●	●	●
Adverse events check		●	●	●	●	●	●	●

●, check on visit; ○, if applicable * UV, unscheduled visit (), ** only fertile women, *** Evaluation for the continuation of herbal medicine administration at 5th and 9th weeks.